

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Treatment of extended-spectrum... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1347/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1347" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Treatment of extended-spectrum Î²-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?" />
    
            <meta name="og:title" content="F1000Research Article: Treatment of extended-spectrum &beta;-lactamase-producing &lt;i&gt;Enterobacteriaceae &lt;/i&gt;(ESBLs) infections: what have we learned until now?.">
            <meta name="og:description" content="Read the latest article version by Zoi Dorothea Pana, Theoklis Zaoutis, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16132">
            <meta name="article-id" content="14822">
            <meta name="dc.title" content="Treatment of extended-spectrum &beta;-lactamase-producing &lt;i&gt;Enterobacteriaceae &lt;/i&gt;(ESBLs) infections: what have we learned until now?">
            <meta name="dc.description" content="The spread of extended-spectrum &beta;-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this &ldquo;evolving crisis&rdquo; is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between &ldquo;Scylla and Charybdis&rdquo;: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization&rsquo;s warning against a &ldquo;post antibiotic era&rdquo;, health-care providers are at a critical standpoint to find a &ldquo;balance&rdquo; between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.">
            <meta name="dc.subject" content="lactamase producers, ESBL treatment, Enterobacteriaceae">
            <meta name="dc.creator" content="Pana, Zoi Dorothea">
            <meta name="dc.creator" content="Zaoutis, Theoklis">
            <meta name="dc.date" content="2018/08/29">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14822.1">
            <meta name="dc.source" content="F1000Research 2018 7:1347">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="lactamase producers">
            <meta name="prism.keyword" content="ESBL treatment">
            <meta name="prism.keyword" content="Enterobacteriaceae">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/08/29">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1347">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14822.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1347">
            <meta name="citation_title" content="Treatment of extended-spectrum &beta;-lactamase-producing &lt;i&gt;Enterobacteriaceae &lt;/i&gt;(ESBLs) infections: what have we learned until now?">
            <meta name="citation_abstract" content="The spread of extended-spectrum &beta;-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this &ldquo;evolving crisis&rdquo; is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between &ldquo;Scylla and Charybdis&rdquo;: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization&rsquo;s warning against a &ldquo;post antibiotic era&rdquo;, health-care providers are at a critical standpoint to find a &ldquo;balance&rdquo; between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.">
            <meta name="citation_description" content="The spread of extended-spectrum &beta;-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this &ldquo;evolving crisis&rdquo; is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between &ldquo;Scylla and Charybdis&rdquo;: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization&rsquo;s warning against a &ldquo;post antibiotic era&rdquo;, health-care providers are at a critical standpoint to find a &ldquo;balance&rdquo; between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.">
            <meta name="citation_keywords" content="lactamase producers, ESBL treatment, Enterobacteriaceae">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Zoi Dorothea Pana">
            <meta name="citation_author_institution" content="Infectious Diseases Department, 3rd Department of Pediatrics, Hippokration General Hospital Aristotle University, Thessaloniki, Greece">
            <meta name="citation_author" content="Theoklis Zaoutis">
            <meta name="citation_author_institution" content="Infectious Diseases Department, The Children&rsquo;s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA">
            <meta name="citation_publication_date" content="2018/08/29">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1347">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14822.1">
            <meta name="citation_firstpage" content="1347">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1347/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1347.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16132 /> <input type=hidden id=articleId name=articleId value=14822 /> <input type=hidden id=xmlUrl value="/articles/7-1347/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1347-v1.xml"> <input type=hidden id=article_uuid value=60d938ba-2430-4045-bf09-c48fdce4da42 /> <input type=hidden id=referer value=""/> <input type="hidden" id="meta-article-title" value="Treatment of extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae </i>(ESBLs) infections: what have we learned until now?" /> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14822.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14822.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1347"
  },
  "headline": "Treatment of extended-spectrum Î²-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have...",
  "datePublished": "2018-08-29T09:20:46",
  "dateModified": "2018-08-29T09:20:46",
  "author": [
    {
      "@type": "Person",
      "name": "Zoi Dorothea Pana"
    },    {
      "@type": "Person",
      "name": "Theoklis Zaoutis"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The spread of extended-spectrum &beta;-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this &ldquo;evolving crisis&rdquo; is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between &ldquo;Scylla and Charybdis&rdquo;: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization&rsquo;s warning against a &ldquo;post antibiotic era&rdquo;, health-care providers are at a critical standpoint to find a &ldquo;balance&rdquo; between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1347.html",
            "name": "Treatment of extended-spectrum Î²-lactamase-producing Enterobacteriaceae..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Treatment of extended-spectrum Î²-lactamase-producing Enterobacteriaceae... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16132 data-id=14822 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14822.1" data-recommended="" data-doi="10.12688/f1000research.14822.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1347/v1/pdf?article_uuid=60d938ba-2430-4045-bf09-c48fdce4da42" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14822-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14822-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14822-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Pana ZD and Zaoutis T. Treatment of extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae </i>(ESBLs) infections: what have we learned until now? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1347 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14822.1" target=_blank>https://doi.org/10.12688/f1000research.14822.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14822-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14822 id=track-article-signin-14822 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14822?target=/articles/7-1347.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16132 /> <input name=articleId type=hidden value=14822 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Treatment of extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae </i>(ESBLs) infections: what have we learned until now?</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Zoi Dorothea Pana<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:zaoutis@email.chop.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Theoklis Zaoutis</span></a><a href="https://orcid.org/0000-0002-5893-1081" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5893-1081</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Zoi Dorothea Pana<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:zaoutis@email.chop.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Theoklis Zaoutis</span></a><a href="http://orcid.org/0000-0002-5893-1081" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5893-1081</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 29 Aug 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14822.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Infectious Diseases Department, 3rd Department of Pediatrics, Hippokration General Hospital Aristotle University, Thessaloniki, Greece<br/> <sup>2</sup> Infectious Diseases Department, The Children&rsquo;s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA<br/> <p> <div class=margin-bottom> Zoi Dorothea Pana <br/> <span>Roles: </span> Writing â Original Draft Preparation </div> <div class=margin-bottom> Theoklis Zaoutis <br/> <span>Roles: </span> Writing â Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=38332-37545></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=26696-37546></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The spread of extended-spectrum Î²-lactamase (ESBL)-producing <i>Enterobacteriaceae</i> (ESBL-PE) has dramatically increased worldwide, and this âevolving crisisâ is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between âScylla and Charybdisâ: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organizationâs warning against a âpost antibiotic eraâ, health-care providers are at a critical standpoint to find a âbalanceâ between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> lactamase producers, ESBL treatment, Enterobacteriaceae </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Theoklis Zaoutis (<a href="mailto:zaoutis@email.chop.edu">zaoutis@email.chop.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Theoklis Zaoutis </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; Â© 2018 Pana ZD and Zaoutis T. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Pana ZD and Zaoutis T. Treatment of extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae </i>(ESBLs) infections: what have we learned until now? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1347 (<a href="https://doi.org/10.12688/f1000research.14822.1" target=_blank>https://doi.org/10.12688/f1000research.14822.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 29 Aug 2018, <b>7</b>(F1000 Faculty Rev):1347 (<a href="https://doi.org/10.12688/f1000research.14822.1" target=_blank>https://doi.org/10.12688/f1000research.14822.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 29 Aug 2018, <b>7</b>(F1000 Faculty Rev):1347 (<a href="https://doi.org/10.12688/f1000research.14822.1" target=_blank>https://doi.org/10.12688/f1000research.14822.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d839e160>Introduction</h2><p class="" id=d839e163>Extended-spectrum Î²-lactamase (ESBL) enzymes are characterized by the ability to hydrolyze third-generation cephalosporins and aztreonam but are inhibited by clavulanic acid. The spread of ESBL-producing <i>Enterobacteriaceae</i> (ESBL-PE) has dramatically increased worldwide, and this âevolving crisisâ is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between âScylla and Charybdisâ: on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. A multicenter study in the US reported that in 2012 the prevalence of ESBL-producing <i>Klebsiella pneumoniae</i> reached 16% and almost 12% for ESBL-producing <i>Escherichia coli</i> and that rates were much higher among intensive care unit (ICU) patients<sup><a href="#ref-1">1</a></sup>. Even in the pediatric population, a meta-analysis revealed that the worldwide prevalence of ESBL producers was estimated to be 9% (11% neonates and 5% children) with an annual increase of 3.2% and a wide variability among different geographic regions (15% in Africa, 12% in South America, 11% in India, 7% in the rest of Asia, and 4% in Europe)<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d839e183>ESBL-PE are associated with increased morbidity and mortality rates, prolonged hospital stays, and increased costs. In a matched cohort study, the nosocomial financial burden of non-urinary tract infections (non-UTIs) caused by ESBL producers was 1.7 times higher compared with the same type of infections caused by non-ESBL producers<sup><a href="#ref-3">3</a></sup>. A case control study in Canada showed that ESBL-PE infections were significantly associated with increased cost (C$10,507 versus C$7,882), hospitalization (8 versus 6 days), and mortality rates (17% versus 5%)<sup><a href="#ref-4">4</a></sup>. In addition, data regarding the rates of ESBL-PE colonization (both health-care or community acquired) reveal an increasing trend over time with significant differences among several geographical regions and patient groups<sup><a href="#ref-5">5</a></sup>. For high-risk patients in the ICU, the ESBL-PE colonization rates might range from 2.3% for the US to 49% for India. According to a recently published systematic review, the most frequently reported risk factor for ESBL-PE colonization and infection remains prior exposure to antimicrobials as well as recent hospitalization and recent or repeated surgery<sup><a href="#ref-5">5</a></sup>. Although prior ESBL-PE colonization has been shown in a few studies to increase the risk of acquiring an ESBL-PE infection, further data are needed.</p><p class="" id=d839e202>Given the World Health Organization (WHO) warning against a âpost antibiotic eraâ, health-care providers are at a critical standpoint to find a âbalanceâ between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of this review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d839e208>Before starting ESBL treatment</h2><p class="" id=d839e211>The first step before initiating ESBL-PE antimicrobial treatment is to carefully evaluate specific parameters that are directly associated with ESBL-PE therapeutic decision making. Of utmost importance is to clearly characterize (a) the isolate with the <i>in vitro</i> susceptibilities, (b) the location of the infection, (c) the degree of source control of the infection, and finally (d) the clinical condition of the patient (<a href="#T1">Table 1</a>). In addition, recently published studies propose that all ESBL-PE do not belong in the same homogenous group as far as comorbidities, presentation, and outcome are concerned<sup><a href="#ref-6">6</a></sup>. In particular, data have shown that bloodstream infections (BSIs) associated with ESBL-producing <i>E. coli</i> were more frequently of a urinary source and community onset compared with BSIs with ESBL-producing <i>Klebsiella</i> spp.<sup><a href="#ref-6">6</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Significant parameters for extended-spectrum Î²-lactamase-producing Enterobacteriaceae (ESBL-PE) antimicrobial treatment.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d839e246 class=n-a></a><thead><a name=d839e248 class=n-a></a><tr><a name=d839e250 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d839e252 class=n-a></a>Infectionâs location</th><th align=left colspan=1 rowspan=1 valign=top><a name=d839e255 class=n-a></a>High-<sup><a href="#FN">a</a></sup> versus low-inoculum infection</th></tr></thead><tbody><a name=d839e264 class=n-a></a><tr><a name=d839e266 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e268 class=n-a></a>Infection source control</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e271 class=n-a></a>Adequate or no source control</td></tr><tr><a name=d839e275 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e277 class=n-a></a>Patientâs clinical condition</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e280 class=n-a></a>Critically ill patient; presence of immunosuppression</td></tr><tr><a name=d839e284 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e286 class=n-a></a>Characterization of multidrug-resistant Gram-negative<br class=br><i>Enterobacteriaceae</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e292 class=n-a></a>Mechanisms associated with ESBL, AmpC, or carbapenem-resistant Enterobacteriaceae </td></tr><tr><a name=d839e296 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e298 class=n-a></a>Evaluation of minimum inhibitory concentration (MIC)<br class=br>susceptibilities</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e303 class=n-a></a>Especially for carbapenems, cefepime, and Î²-lactam/Î²-lactamase<br class=br>inhibitor (BLBLI) combinations</td></tr><tr><a name=d839e309 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e311 class=n-a></a>Type of ESBL-PE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e314 class=n-a></a><i>Klebsiella pneumoniae</i> versus <i>Escherichia coli</i></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d839e326 class=n-a></a><p id=FN> <sup>a</sup>Examples of high-inoculum infections could be large intra-abdominal collections and endocarditis vegetations.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d839e339>Decision making on ESBL-PE antimicrobial treatment</h2><div class=section><a name=d839e342 class=n-a></a><h3 class=section-title>Clinical question 1: Carbapenems <i>or</i> Î²-lactam/Î²-lactamase inhibitor combinations in ESBL-PE infections?</h3><p class="" id=d839e350>Carbapenems possess the broadest spectrum of Î²-lactam antibiotics with greatest potency against Gram-negative bacteria and are characterized by stability to hydrolysis by the majority of Î²-lactamases<sup><a href="#ref-7">7</a></sup>. Several studies have shown that carbapenem treatment is associated with improved outcomes in patients with severe ESBL-PE infections and remains the âgold standardâ treatment for serious and invasive ESBL-PE infections<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Specific considerations among carbapenems are the induction of carbapenem resistance and their side effects, especially as far as their epileptogenic effect is concerned<sup><a href="#ref-10">10</a></sup>. Most studies have evaluated either meropenem or imipenem for the treatment of ESBL-PE, although a recently published multinational retrospective study compared the clinical efficacy of ertapenem with that of other carbapenems in ESBL-PE BSIs<sup><a href="#ref-11">11</a></sup>. Cure rates were similar (90.6% with ertapenem and 75.5% with other carbapenems in empiric and 89.8% and 82.6% in targeted treatment), and no differences have been observed for mortality among the two groups, but for patients with severe sepsis a non-significant trend favoring other carbapenems was observed<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d839e376>Among Î²-lactam/Î²-lactamase inhibitor (BLBLI) combinations, the combination of piperacillinâtazobactam (PTZ) has been extensively studied as an alternative carbapenem-sparing option against ESBL-PE infections<sup><a href="#ref-12">12</a></sup>. In 2012, a meta-analysis compared the mortality rates among carbapenems and alternative regimens, including BLBLIs, for the treatment of ESBL-PE BSIs<sup><a href="#ref-13">13</a></sup>. According to their results, differences were noticed in mortality rates when administered as either definitive or empirical therapy, although they mentioned one studyâs significant heterogeneity<sup><a href="#ref-13">13</a></sup>. Since the question about the role of BLBLIs remained, six subsequent studies from 2012 to 2017 tried to elucidate the role of BLBLIs against ESBL-PE with rather conflicting results<sup><a href="#ref-14">14</a>â<a href="#ref-18">18</a></sup>. These controversies were interpreted by substantial differences among the studiesâ design. In particular, the Spanish groups included mainly <i>E. coli</i> as the attributed ESBL-PE, and their studies had lower inoculum infections, ICU admissions, and median PTZ minimum inhibitory concentration (MIC) and higher PTZ treatment dosages compared with the study by Tamma <i>et al</i>.<sup><a href="#ref-9">9</a>,<a href="#ref-15">15</a>,<a href="#ref-18">18</a></sup>. A further analysis of cases of the Spanish group, conducted by Retamar <i>et al</i>., revealed that all patients who presented with ESBL-PE BSIs from a urinary source had a favorable outcome, irrespectively of the PTZ MIC<sup><a href="#ref-19">19</a></sup>. Furthermore, among patients with an ESBL-PE BSI with a source other than a urinary one, the outcome was dismal when the MIC of the isolate for PTZ was more than 2 mg/L<sup><a href="#ref-19">19</a></sup>. A recently published randomized controlled trial was conducted comparing PTZ, cefepime, and ertapenem for the treatment of ESBL-PE UTIs caused by <i>E. coli</i><sup><a href="#ref-20">20</a></sup>. Based on the results, the clinical and microbiological response to PTZ treatment was estimated to be 94% and was similar to the response to ertapenem treatment. An ongoing retrospective observational study (BICAR) is trying to evaluate the efficacy of BLBLI combinations for the treatment of ESBL-PE BSIs in hematological patients with neutropenia<sup><a href="#ref-21">21</a></sup>. In addition, a recently published propensity score-weighted multicenter cohort study in Korea showed that, among 232 patients with ESBL-PE BSIs, non-carbapenem regimens were not inferior to carbapenems (30-day mortality rates for non-carbapenems 6.3% versus carbapenems 11.4%)<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d839e441><b><i>Authorsâ recommendations.</i></b> For invasive, high-inoculum ESBL-PE infections with a source of infection other than <i>E. coli</i> and in critically ill patients, carbapenems remain the âgold standardâ of targeted treatment. Especially for ICU patients, according to a recent systematic review, the empirical use of PTZ when high risk of ESBL-PE is suspected should be avoided<sup><a href="#ref-23">23</a></sup>. Definitive therapy with BLBLIs should be selected under specific criteria such as stable condition, after microbial documentation with susceptibility results, in combination with dose and infusion modalities to the MIC in order to reach pharmacological targets<sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d839e458>Definite answers concerning the role of BLBLIs (and specifically PTZ) against ESBL-PE BSIs will be given by an ongoing multicenter clinical trial (MERINO trial) comparing PTZ versus carbapenems for the definitive treatment of BSIs caused by ceftriaxone-resistant <i>E. coli</i> and <i>Klebsiella</i> spp.<sup><a href="#ref-24">24</a></sup>. Based on the preliminary MERINO results presented at European Congress of Clinical Microbiology &amp; Infectious Diseases 2018, the most common ESBL-PE bacteremia source was the urinary tract (60.9%) with clear predominance of <i>E. coli</i> (86.5%). Although no difference between the two groups regarding subsequent infections of drug-resistant bacteria or <i>C. difficile</i> was reported, the 30-day mortality rate differed (12.3% for PTZ versus 3.7% for meropenem)<sup><a href="#ref-25">25</a></sup>. In addition, it is of utmost importance to clearly define in future studies the specific subset of patients with ESBL-PE infections who could benefit from carbapenem-sparing treatments, especially regarding hematological patients with neutropenia<sup><a href="#ref-26">26</a></sup>.</p></div><div class=section><a name=d839e487 class=n-a></a><h3 class=section-title>Clinical question 2: What is the role of cefepime in treating ESBL-PE infections?</h3><p class="" id=d839e492>The results from published studies and reviews evaluating the efficacy of cefepime versus carbapenems for the treatment of ESBL-PE infections remain controversial. Few studies have shown comparable efficacy, whereas others reported significant inferiority of cefepime<sup><a href="#ref-27">27</a>â<a href="#ref-31">31</a></sup>. Among these studies, Lee <i>et al.</i><sup><a href="#ref-31">31</a></sup> and Wang <i>et al.</i><sup><a href="#ref-27">27</a></sup> showed significantly lower mortality rates at 30 and 14 days, respectively (17% versus 59% and 41% versus 20%, respectively). In particular, in the study by Lee <i>et al</i>., a significant association was observed between the mortality rates of the patients receiving cefepime and the MIC of the drug. In particular, for cefepime MIC of not more than 1 Î¼g/mL, the mortality rate was 16.7%; for MIC of 2â8 Î¼g/mL, the rates reached 45.5%; while for MIC of at least 16 Î¼g/mL, the rates were 100% (<i>p</i> = 0.035)<sup><a href="#ref-31">31</a></sup>. Even after propensity score adjustment, cefepime remained inferior compared with<i></i> carbapenem (adjusted odds ratio 6.8, 95% confidence interval (CI) 1.5â31.2, <i>p</i> = 0.01). A subsequent randomized controlled trial was conducted comparing PTZ, cefepime, and ertapenem for the treatment of ESBL-PE UTIs caused by <i>E. coli</i> showing inferiority of cefepime compared with the other treatment options. The efficacy of cefepime was 33.3% compared with 94% efficacy of PTZ treatment<sup><a href="#ref-20">20</a></sup>.</p><p class="" id=d839e537><b><i>Authorsâ recommendations.</i></b> For serious invasive ESBL-PE infections with high inoculum and lack of source control, cefepime seems to be inferior compared with carbapenems because of two significant issues: increased MICs of the drug because of high inoculum effect and failure to achieve its pharmacodynamic targets in severe ESBL-PE infections. Cefepime could be administered only in non-severe ESBL-PE UTIs, where high drug concentrations could be achieved and when simultaneously low MIC of the drug is reported (MICs â¤2 Î¼g/mL).</p></div><div class=section><a name=d839e544 class=n-a></a><h3 class=section-title>Clinical question 3: What is the role for fosfomycin, aminoglycosides, or temocillin in ESBL-PE infections?</h3><p class="" id=d839e549>Fosfomycin is an old bactericidal antibiotic agent (phosphonic compound) with a unique mode of action of inhibiting bacterial cell wall biosynthesis<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. A recently published literature review concerning the susceptibility of contemporary Gram-negative bacteria revealed that, for ESBL-producing <i>E. coli</i>, susceptibilities ranged from 81% to 100% and, for ESBL-producing <i>K. pneumoniae</i>, from 15% to 100%<sup><a href="#ref-34">34</a></sup>. Owing to its low molecular weight, its hydrophilicity, and its negligible serum protein binding, the drug achieves good tissue penetration and high concentrations in the serum, soft tissue, lungs, bone, cerebrospinal fluid, and heart valves<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>. Especially for the urinary tract, the drug achieves high concentrations for a prolonged period of time. Finally, in critically ill patients, a significant increase of fosfomycin volume of distribution is observed; therefore, the current paucity of data on fosfomycin in critically ill patients prevents accurate dosing guidance<sup><a href="#ref-36">36</a></sup>. Clinical data concerning the efficacy of intravenous fosfomycin against ESBL-PE invasive infections are very limited and focus mainly on UTI treatment<sup><a href="#ref-32">32</a>,<a href="#ref-37">37</a>â<a href="#ref-42">42</a></sup>. A randomized clinical trial (âFORESTâ) comparing the safety and efficacy of fosfomycin versus meropenem in bacteremic UTIs caused by ESBL-producing <i>E. coli</i> is ongoing<sup><a href="#ref-38">38</a></sup>. Fosfomycin as monotherapy for the treatment of multidrug-resistant organism (MDRO)-associated invasive infections is limited by the emergence of drug resistance to fosfomycin during treatment<sup><a href="#ref-39">39</a></sup>. A more recently published meta-analysis conducted by Grabein <i>et al.</i> tried to summarize the current clinical evidence of intravenous fosfomycin in 128 studies<sup><a href="#ref-43">43</a></sup>. According to their results, the drug showed comparable clinical or microbiological efficacy compared with other antibiotics when used for sepsis/bacteremia, urinary tract, respiratory tract, bone and joint, and central nervous system infections<sup><a href="#ref-43">43</a></sup>. The pooled estimate for resistance development during fosfomycin monotherapy was 3.4% (95% CI 1.8%â5.1%). <b></b></p><p class="" id=d839e615>Up-to-date data concerning the role of aminoglycosides in combating MDRO infections showed that for ESBL infections they can be used as part of a combination regimen, especially for UTIs and intra-abdominal infections (IAIs), as a carbapenem-sparing option<sup><a href="#ref-8">8</a></sup>. An <i>in vitro</i> synergistic effect has been confirmed for the concomitant administration of aminoglycosides plus Î²-lactams, while the monotherapy is not generally recommended for ESBL-PE infections, except for ESBL-PE non-bacteremic UTIs, mainly owing to the high risk of resistance development<sup><a href="#ref-44">44</a>â<a href="#ref-47">47</a></sup>. Among newer aminoglycosides, plazomicin (formerly ACHN-490), a next-generation aminoglycoside synthetically derived from sisomicin, is recently gaining more attention against MDRO infections<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. The unique characteristic of plazomicin is its resistance to inactivation by aminoglycoside-modifying enzymes compared with other agents of the same group<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. However, plazomicin is not active against bacterial isolates expressing ribosomal methyltransferases<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. In two studies, plazomicin has been shown to be more potent than other aminoglycosides in treating <i>Enterobacteriaceae</i><sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>.</p><p class="" id=d839e663>Temocillin is a Î²-lactamase-resistant carboxypenicillin active against both ESBL-PE and AmpC-producing <i>Enterobacteriaceae</i> and with limited activity against <i>Pseudomonas</i>, <i>Acinetobacter</i> spp., and anaerobic bacteria. Although this carbapenem-sparing drug option is licensed in only a few European countries (UK and Belgium), data from a multicenter study in the UK among 92 infection episodes (42 BSIs) treated with temocillin showed promising results<sup><a href="#ref-51">51</a></sup>. In particular, both clinical and microbiological cure rates were reported to be 86% and 84%<sup><a href="#ref-51">51</a></sup>. In addition, a prospective randomized controlled trial conducted in Belgium in 2014 showed that for critically ill patients the optimal dose regimen for temocillin in order to achieve its pharmacological targets with longer free-serum concentrations is 2 g three times a day administered by continuous infusion<sup><a href="#ref-52">52</a></sup>.</p><p class="" id=d839e688><b><i>Authorsâ recommendations.</i></b> Fosfomycin is strongly suggested for ESBL-PE UTIs and as a step-down therapy in source-controlled ESBL-PE infections. A randomized clinical trial (âFORESTâ) comparing the safety and efficacy of fosfomycin versus meropenem in bacteremic UTIs caused by ESBL-producing <i>E. coli</i> is ongoing<sup><a href="#ref-41">41</a></sup>. Other options of source-controlled ESBL-PE UTIs are aminoglycosides, especially for cystitis infections. In addition, they can be used as part of a combination regimen, especially for UTIs and IAIs, as a carbapenem-sparing option<sup><a href="#ref-8">8</a></sup>. For temocillin, larger clinical studies among different patient groups are needed in order to establish their role as a valuable carbapenem-sparing option against ESBL-PE BSIs.</p></div><div class=section><a name=d839e706 class=n-a></a><h3 class=section-title>Clinical question 4: What is the role of the newly approved drugs against ESBL-PE infections?</h3><p class="" id=d839e711>In <a href="#T2">Table 2</a>, some of the new drugs active against multidrug-resistant bacteria, including ESBL-producing ones, are reported. Among newer BLBLIs developed, two of themâceftazidimeâavibactam and ceftolozaneâtazobactamâhave already received US Food and Drug Administration (FDA) approval and therefore will be discussed further.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. New drugs with <i>in vitro</i> activity against extended-spectrum Î²-lactamase-producing Enterobacteriaceae (ESBL-PE).</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d839e731 class=n-a></a><thead><a name=d839e733 class=n-a></a><tr><a name=d839e735 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d839e737 class=n-a></a>New drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d839e740 class=n-a></a><i>In vitro</i> activity</th></tr></thead><tbody><a name=d839e747 class=n-a></a><tr><a name=d839e749 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e751 class=n-a></a>Ceftazidimeâavibactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e754 class=n-a></a><b>ESBL</b><br class=br>AmpC<br class=br><i>Klebsiella pneumoniae</i> carbapenemase (KPC)<br class=br>OXA-48<br class=br>Not active against metallo-Î²-lactamase (MBL)</td></tr><tr><a name=d839e769 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e771 class=n-a></a>Ceftarolineâavibactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e774 class=n-a></a><b>ESBL</b><br class=br>Methicillin-resistant <i>Staphylococcus aureus</i> AmpC<br class=br>KPC<br class=br>OXA-48?</td></tr><tr><a name=d839e788 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e790 class=n-a></a>Ceftolozaneâtazobactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e793 class=n-a></a><b>ESBL</b><br class=br>Some AmpC<br class=br>Multidrug-resistant <i>Pseudomonas aeruginosa</i> </td></tr><tr><a name=d839e805 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e807 class=n-a></a>Imipenemârelebactam</td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e810 class=n-a></a><b>ESBL</b><br class=br>AmpC<br class=br>KPC<br class=br>OXA-48<br class=br>Not active against MBL</td></tr><tr><a name=d839e823 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d839e825 class=n-a></a>Plazomicin </td><td align=left colspan=1 rowspan=1 valign=top><a name=d839e828 class=n-a></a><b>ESBL</b><br class=br>AmpC<br class=br>KPC<br class=br>OXA<br class=br>VIM<br class=br>Not active against some NDM</td></tr></tbody></table></div><p class="" id=d839e846>Ceftazidimeâavibactam is a combination of cephalosporin with a new non-BLBLI that is generally active against <i>Enterobacteriaceae</i> and <i>P. aeruginosa</i> producing class A Î²-lactamases (ESBLs and KPCs) and class C Î²-lactamases (AmpCs) and some <i>Enterobacteriaceae</i> producing class D Î²-lactamases (OXAs) but lacks activity against class B carbapenemases and is less active against anaerobes compared with other BLBLIs. A phase 3 trial (RECLAIM 1 and RECLAIM 2) conducted by Mazuski <i>et al.</i> evaluated the efficacy of ceftazidimeâavibactam in treating complicated IAI (cIAI), revealing non-inferiority of the tested combination drug and similar clinical cure rates of 81.6% versus 85.1%, respectively<sup><a href="#ref-53">53</a></sup>. A subsequent phase 3 (REPRISE) study by Carmeli <i>et al.</i> recently published the results of the efficacy of ceftazidimeâavibactamâ2 to 0.5 g intravenously every 8 hours (q8h)âversus the best available therapy both for complicated UTI or cIAI due to ceftazidime-resistant <i>Enterobacteriaceae</i> or <i>P. aeruginosa</i> with similar clinical cure rates<sup><a href="#ref-54">54</a></sup>. Finally, in 2015, the drug was approved by the FDA for complicated UTIs and cIAI with a recommended dosage of 2 g/0.5 g) 8 hourly for 7 days for UTIs and 4 to 14 days for IAIs with dose adjustment in renal insufficiency. An ongoing clinical trial is evaluating the safety and efficacy profile of the drug for nosocomial pneumonia<sup><a href="#ref-55">55</a></sup>.</p><p class="" id=d839e883>Ceftolozaneâtazobactam is a co-formulation of a novel cephalosporin with an old Î²-lactamase inhibitor. Ceftolozane is a new cephalosporin based on the scaffold of ceftazidimeâwith only one modification of the side chain at the 3-position of the cephem nucleusâwith improved activity against multidrug-resistant <i>Pseudomonas</i> spp. Ceftolozane, like other oxyimino-cephalosporins such as ceftazidime and ceftriaxone, is not stable against class A, B, or D Î²-lactamases (mainly ESBLs or carbapenemases). The combination with tazobactam significantly broadens its spectrum against ESBL-PE and against few anaerobes<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. In 2014, the FDA approved the administration of the combination drug for the treatment of complicated UTIs and cIAIs based on previously published clinical trials (ASPECT trials)<sup><a href="#ref-58">58</a>â<a href="#ref-60">60</a></sup>. In particular, the drug was evaluated in phase 3 non-inferiority clinical trials versus levofloxacin 750 mg daily in complicated UTI or meropenem 1 g q8h in cIAI. The UTI trial compared ceftolozane 1,000 mg q8h versus ceftazidime 1,000 mg q8h, including pyelonephritis, and demonstrated similar microbiologic and clinical outcomes, as well as a similar incidence of adverse effects after 7 to 10 days of treatment, respectively. The second cIAI trial has been conducted comparing ceftolozaneâtazobactam 1,000/500 mg and metronidazole 500 mg q8h versus meropenem 1,000 mg q8h in the treatment of cIAI. The recommended FDA dosage is 1 g/0.5 g 8 hourly for 7 days in complicated UTIs and 4 to 14 days in cIAIs, respectively<sup><a href="#ref-61">61</a></sup>.</p></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d839e1 class=n-a></a><h2 class=main-title id=d1033>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d839e912 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d1243>References</h2><div class="section ref-list"><a name=d839e912 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d839e919 class=n-a></a>Morrissey I, Hackel M, Badal R, <i> et al.</i>: A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. <i>Pharmaceuticals (Basel).</i> 2013; <b>6</b>(11): 1335â46. <a target=xrefwindow id=d839e930 href="http://www.ncbi.nlm.nih.gov/pubmed/24287460">PubMed Abstract </a> | <a target=xrefwindow id=d839e933 href="http://dx.doi.org/10.3390/ph6111335">Publisher Full Text </a> | <a target=xrefwindow id=d839e937 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3854014">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727254349"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e946 class=n-a></a>Flokas ME, Karanika S, Alevizakos M, <i> et al.</i>: Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis. <i>PLoS One.</i> 2017; <b>12</b>(1): e0171216. <a target=xrefwindow id=d839e957 href="http://www.ncbi.nlm.nih.gov/pubmed/28141845">PubMed Abstract </a> | <a target=xrefwindow id=d839e960 href="http://dx.doi.org/10.1371/journal.pone.0171216">Publisher Full Text </a> | <a target=xrefwindow id=d839e964 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5283749">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727254349">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1048192"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e977 class=n-a></a>Lee SY, Kotapati S, Kuti JL, <i> et al.</i>: Impact of extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella</i> species on clinical outcomes and hospital costs: a matched cohort study. <i>Infect Control Hosp Epidemiol.</i> 2006; <b>27</b>(11): 1226â32. <a target=xrefwindow id=d839e995 href="http://www.ncbi.nlm.nih.gov/pubmed/17080381">PubMed Abstract </a> | <a target=xrefwindow id=d839e998 href="http://dx.doi.org/10.1086/507962">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1048192">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726075285"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1011 class=n-a></a>Maslikowska JA, Walker SA, Elligsen M, <i> et al.</i>: Impact of infection with extended-spectrum Î²-lactamase-producing <i>Escherichia coli</i> or <i>Klebsiella</i> species on outcome and hospitalization costs. <i>J Hosp Infect.</i> 2016; <b>92</b>(1): 33â41. <a target=xrefwindow id=d839e1029 href="http://www.ncbi.nlm.nih.gov/pubmed/26597637">PubMed Abstract </a> | <a target=xrefwindow id=d839e1032 href="http://dx.doi.org/10.1016/j.jhin.2015.10.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726075285">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728185117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1045 class=n-a></a>Biehl LM, Schmidt-Hieber M, Liss B, <i> et al.</i>: Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. <i>Crit Rev Microbiol.</i> 2016; <b>42</b>(1): 1â16. <a target=xrefwindow id=d839e1056 href="http://www.ncbi.nlm.nih.gov/pubmed/24495097">PubMed Abstract </a> | <a target=xrefwindow id=d839e1059 href="http://dx.doi.org/10.3109/1040841X.2013.875515">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728185117">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732991349"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1073 class=n-a></a>Scheuerman O, Schechner V, Carmeli Y, <i> et al.</i>: Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i>. <i>Infect Control Hosp Epidemiol.</i> 2018; <b>39</b>(6): 660â7. <a target=xrefwindow id=d839e1091 href="http://www.ncbi.nlm.nih.gov/pubmed/29618394">PubMed Abstract </a> | <a target=xrefwindow id=d839e1094 href="http://dx.doi.org/10.1017/ice.2018.63">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732991349">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d839e1107 class=n-a></a>Papp-Wallace KM, Endimiani A, Taracila MA, <i> et al.</i>: Carbapenems: past, present, and future. <i>Antimicrob Agents Chemother.</i> 2011; <b>55</b>(11): 4943â60. <a target=xrefwindow id=d839e1118 href="http://www.ncbi.nlm.nih.gov/pubmed/21859938">PubMed Abstract </a> | <a target=xrefwindow id=d839e1121 href="http://dx.doi.org/10.1128/AAC.00296-11">Publisher Full Text </a> | <a target=xrefwindow id=d839e1125 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3195018">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726703805"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1134 class=n-a></a>Bassetti M, Peghin M, Pecori D: The management of multidrug-resistant Enterobacteriaceae. <i>Curr Opin Infect Dis.</i> 2016; <b>29</b>(6): 583â94. <a target=xrefwindow id=d839e1142 href="http://www.ncbi.nlm.nih.gov/pubmed/27584587">PubMed Abstract </a> | <a target=xrefwindow id=d839e1145 href="http://dx.doi.org/10.1097/QCO.0000000000000314">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726703805">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d839e1158 class=n-a></a>Tamma PD, Han JH, Rock C, <i> et al.</i>: Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum Î²-lactamase bacteremia. <i>Clin Infect Dis.</i> 2015; <b>60</b>(9): 1319â25. <a target=xrefwindow id=d839e1169 href="http://www.ncbi.nlm.nih.gov/pubmed/25586681">PubMed Abstract </a> | <a target=xrefwindow id=d839e1172 href="http://dx.doi.org/10.1093/cid/civ003">Publisher Full Text </a> | <a target=xrefwindow id=d839e1176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4462658">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d839e1185 class=n-a></a>Cannon JP, Lee TA, Clark NM, <i> et al.</i>: The risk of seizures among the carbapenems: a meta-analysis. <i>J Antimicrob Chemother.</i> 2014; <b>69</b>(8): 2043â55. <a target=xrefwindow id=d839e1196 href="http://www.ncbi.nlm.nih.gov/pubmed/24744302">PubMed Abstract </a> | <a target=xrefwindow id=d839e1199 href="http://dx.doi.org/10.1093/jac/dku111">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726173312"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1208 class=n-a></a>GutiÃ©rrez-GutiÃ©rrez B, Bonomo RA, Carmeli Y, <i> et al.</i>: Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>J Antimicrob Chemother.</i> 2016; <b>71</b>(6): 1672â80. <a target=xrefwindow id=d839e1219 href="http://www.ncbi.nlm.nih.gov/pubmed/26907184">PubMed Abstract </a> | <a target=xrefwindow id=d839e1222 href="http://dx.doi.org/10.1093/jac/dkv502">Publisher Full Text </a> | <a target=xrefwindow id=d839e1226 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4867097">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726173312">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732651611"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1240 class=n-a></a>Sheu CC, Lin SY, Chang YT, <i> et al.</i>: Management of infections caused by extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae</i>: current evidence and future prospects. <i>Expert Rev Anti Infect Ther.</i> 2018; <b>16</b>(3): 205â18. <a target=xrefwindow id=d839e1254 href="http://www.ncbi.nlm.nih.gov/pubmed/29402125">PubMed Abstract </a> | <a target=xrefwindow id=d839e1258 href="http://dx.doi.org/10.1080/14787210.2018.1436966">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732651611">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717954748"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1271 class=n-a></a>Vardakas KZ, Tansarli GS, Rafailidis PI, <i> et al.</i>: Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum Î²-lactamases: a systematic review and meta-analysis. <i>J Antimicrob Chemother.</i> 2012; <b>67</b>(12): 2793â803. <a target=xrefwindow id=d839e1282 href="http://www.ncbi.nlm.nih.gov/pubmed/22915465">PubMed Abstract </a> | <a target=xrefwindow id=d839e1285 href="http://dx.doi.org/10.1093/jac/dks301">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717954748">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d839e1298 class=n-a></a>Kang CI, Chung DR, Ko KS, <i> et al.</i>: Risk factors for infection and treatment outcome of extended-spectrum Î²-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bacteremia in patients with hematologic malignancy. <i>Ann Hematol.</i> 2012; <b>91</b>(1): 115â21. <a target=xrefwindow id=d839e1316 href="http://www.ncbi.nlm.nih.gov/pubmed/21556875">PubMed Abstract </a> | <a target=xrefwindow id=d839e1319 href="http://dx.doi.org/10.1007/s00277-011-1247-7">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d839e1328 class=n-a></a>RodrÃ­guez-BaÃ±o J, Navarro MD, Retamar P, <i> et al.</i>: Î²-Lactam/Î²-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum Î²-lactamase-producing <i>Escherichia coli</i>: a post hoc analysis of prospective cohorts. <i>Clin Infect Dis.</i> 2012; <b>54</b>(2): 167â74. <a target=xrefwindow id=d839e1342 href="http://www.ncbi.nlm.nih.gov/pubmed/22057701">PubMed Abstract </a> | <a target=xrefwindow id=d839e1346 href="http://dx.doi.org/10.1093/cid/cir790">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d839e1355 class=n-a></a>Harris PN, Yin M, Jureen R, <i> et al.</i>: Comparable outcomes for Î²-lactam/Î²-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i>. <i>Antimicrob Resist Infect Control.</i> 2015; <b>4</b>: 14. <a target=xrefwindow id=d839e1373 href="http://www.ncbi.nlm.nih.gov/pubmed/25932324">PubMed Abstract </a> | <a target=xrefwindow id=d839e1376 href="http://dx.doi.org/10.1186/s13756-015-0055-6">Publisher Full Text </a> | <a target=xrefwindow id=d839e1379 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4414382">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d839e1388 class=n-a></a>Ofer-Friedman H, Shefler C, Sharma S, <i> et al.</i>: Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. <i>Infect Control Hosp Epidemiol.</i> 2015; <b>36</b>(8): 981â5. <a target=xrefwindow id=d839e1399 href="http://www.ncbi.nlm.nih.gov/pubmed/25990361">PubMed Abstract </a> | <a target=xrefwindow id=d839e1402 href="http://dx.doi.org/10.1017/ice.2015.101">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726327966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1412 class=n-a></a>GutiÃ©rrez-GutiÃ©rrez B, PÃ©rez-Galera S, Salamanca E, <i> et al.</i>: A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing <i>Enterobacteriaceae</i>. <i>Antimicrob Agents Chemother.</i> 2016; <b>60</b>(7): 4159â69. <a target=xrefwindow id=d839e1426 href="http://www.ncbi.nlm.nih.gov/pubmed/27139473">PubMed Abstract </a> | <a target=xrefwindow id=d839e1430 href="http://dx.doi.org/10.1128/AAC.00365-16">Publisher Full Text </a> | <a target=xrefwindow id=d839e1433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4914653">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726327966">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d839e1446 class=n-a></a>Retamar P, LÃ³pez-Cerero L, Muniain MA, <i> et al.</i>: Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-Î²-lactamase-producing <i>Escherichia coli</i>. <i>Antimicrob Agents Chemother.</i> 2013; <b>57</b>(7): 3402â4. <a target=xrefwindow id=d839e1460 href="http://www.ncbi.nlm.nih.gov/pubmed/23612190">PubMed Abstract </a> | <a target=xrefwindow id=d839e1464 href="http://dx.doi.org/10.1128/AAC.00135-13">Publisher Full Text </a> | <a target=xrefwindow id=d839e1467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3697383">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727696331"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1476 class=n-a></a>Seo YB, Lee J, Kim YK, <i> et al.</i>: Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing <i>Escherichia coli</i>. <i>BMC Infect Dis.</i> 2017; <b>17</b>(1): 404. <a target=xrefwindow id=d839e1490 href="http://www.ncbi.nlm.nih.gov/pubmed/28592240">PubMed Abstract </a> | <a target=xrefwindow id=d839e1494 href="http://dx.doi.org/10.1186/s12879-017-2502-x">Publisher Full Text </a> | <a target=xrefwindow id=d839e1497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5463388">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727696331">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d839e1510 class=n-a></a>Gudiol C, Royo-Cebrecos C, Tebe C, <i> et al.</i>: Clinical efficacy of Î²-lactam/Î²-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae</i> in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). <i>BMJ Open.</i> 2017; <b>7</b>(1): e013268. <a target=xrefwindow id=d839e1524 href="http://www.ncbi.nlm.nih.gov/pubmed/28115333">PubMed Abstract </a> | <a target=xrefwindow id=d839e1528 href="http://dx.doi.org/10.1136/bmjopen-2016-013268">Publisher Full Text </a> | <a target=xrefwindow id=d839e1531 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5278288">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732181839"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1540 class=n-a></a>Ko JH, Lee NR, Joo EJ, <i> et al.</i>: Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study. <i>Eur J Clin Microbiol Infect Dis.</i> 2018; <b>37</b>(2): 305â11. <a target=xrefwindow id=d839e1551 href="http://www.ncbi.nlm.nih.gov/pubmed/29177611">PubMed Abstract </a> | <a target=xrefwindow id=d839e1554 href="http://dx.doi.org/10.1007/s10096-017-3133-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732181839">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732104970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1567 class=n-a></a>Pilmis B, Jullien V, Tabah A, <i> et al.</i>: Piperacillin-tazobactam as alternative to carbapenems for ICU patients. <i>Ann Intensive Care.</i> 2017; <b>7</b>(1): 113. <a target=xrefwindow id=d839e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/29127502">PubMed Abstract </a> | <a target=xrefwindow id=d839e1581 href="http://dx.doi.org/10.1186/s13613-017-0334-x">Publisher Full Text </a> | <a target=xrefwindow id=d839e1585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5681454">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732104970">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d839e1599 class=n-a></a>Harris PN, Peleg AY, Iredell J, <i> et al.</i>: Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <i>Escherichia coli</i> and <i>Klebsiella</i> spp (the MERINO trial): study protocol for a randomised controlled trial. <i>Trials.</i> 2015; <b>16</b>: 24. <a target=xrefwindow id=d839e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/25623485">PubMed Abstract </a> | <a target=xrefwindow id=d839e1620 href="http://dx.doi.org/10.1186/s13063-014-0541-9">Publisher Full Text </a> | <a target=xrefwindow id=d839e1623 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4311465">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d839e1632 class=n-a></a>Abstract no: O1121, The MERINO Trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin non-susceptible <i>Escherichia coli</i> or <i>Klebsiella</i> spp.: an international multi-centre open-label non-inferiority randomised controlled trial. session Late breaker: <i>Clinical trials.</i> 16:00 - 18:00, Sunday, 22 April, 2018, Hall Q. <a target=xrefwindow id=d839e1643 href="https://distribute.m-anage.com/from.storage?image=m4NnQJJge6AGNVwgpkCUTNSiXxfyf_3cyFUA4n2Wu_ztdQ7Ijqw93XT4ZqvUMITv0">Reference Source</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d839e1652 class=n-a></a>Tamma PD, Villegas MV: Use of Î²-Lactam/Î²-Lactamase Inhibitors for Extended-Spectrum-Î²-Lactamase Infections: Defining the Right Patient Population. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(8): pii: e01094-17. <a target=xrefwindow id=d839e1660 href="http://www.ncbi.nlm.nih.gov/pubmed/28584153">PubMed Abstract </a> | <a target=xrefwindow id=d839e1663 href="http://dx.doi.org/10.1128/AAC.01094-17">Publisher Full Text </a> | <a target=xrefwindow id=d839e1666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5527567">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726675611"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1675 class=n-a></a>Wang R, Cosgrove SE, Tschudin-Sutter S, <i> et al.</i>: Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum Î²-Lactamase-Producing <i>Enterobacteriaceae</i> Bacteremia. <i>Open Forum Infect Dis.</i> 2016; <b>3</b>(3): ofw132. <a target=xrefwindow id=d839e1689 href="http://www.ncbi.nlm.nih.gov/pubmed/27419191">PubMed Abstract </a> | <a target=xrefwindow id=d839e1693 href="http://dx.doi.org/10.1093/ofid/ofw132">Publisher Full Text </a> | <a target=xrefwindow id=d839e1696 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4942761">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726675611">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d839e1709 class=n-a></a>Goethaert K, Van Looveren M, Lammens C, <i> et al.</i>: High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing <i>Enterobacter aerogenes</i> in severely-ill patients. <i>Clin Microbiol Infect.</i> 2006; <b>12</b>(1): 56â62. <a target=xrefwindow id=d839e1723 href="http://www.ncbi.nlm.nih.gov/pubmed/16460547">PubMed Abstract </a> | <a target=xrefwindow id=d839e1727 href="http://dx.doi.org/10.1111/j.1469-0691.2005.01290.x">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d839e1736 class=n-a></a>Chopra T, Marchaim D, Veltman J, <i> et al.</i>: Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-Î²-lactamase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i>. <i>Antimicrob Agents Chemother.</i> 2012; <b>56</b>(7): 3936â42. <a target=xrefwindow id=d839e1754 href="http://www.ncbi.nlm.nih.gov/pubmed/22547616">PubMed Abstract </a> | <a target=xrefwindow id=d839e1757 href="http://dx.doi.org/10.1128/AAC.05419-11">Publisher Full Text </a> | <a target=xrefwindow id=d839e1760 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3393468">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d839e1770 class=n-a></a>Zanetti G, Bally F, Greub G, <i> et al.</i>: Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. <i>Antimicrob Agents Chemother.</i> 2003; <b>47</b>(11): 3442â7. <a target=xrefwindow id=d839e1781 href="http://www.ncbi.nlm.nih.gov/pubmed/14576100">PubMed Abstract </a> | <a target=xrefwindow id=d839e1784 href="http://dx.doi.org/10.1128/AAC.47.11.3442-3447.2003">Publisher Full Text </a> | <a target=xrefwindow id=d839e1788 href="http://www.ncbi.nlm.nih.gov/pmc/articles/253800">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d839e1797 class=n-a></a>Lee NY, Lee CC, Huang WH, <i> et al.</i>: Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing <i>Enterobacteriaceae</i>: MIC matters. <i>Clin Infect Dis.</i> 2013; <b>56</b>(4): 488â95. <a target=xrefwindow id=d839e1811 href="http://www.ncbi.nlm.nih.gov/pubmed/23090931">PubMed Abstract </a> | <a target=xrefwindow id=d839e1815 href="http://dx.doi.org/10.1093/cid/cis916">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727464249"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1824 class=n-a></a>Tamma PD, Rodriguez-Bano J: The Use of Noncarbapenem Î²-Lactams for the Treatment of Extended-Spectrum Î²-Lactamase Infections. <i>Clin Infect Dis.</i> 2017; <b>64</b>(7): 972â80. <a target=xrefwindow id=d839e1832 href="http://www.ncbi.nlm.nih.gov/pubmed/28362938">PubMed Abstract </a> | <a target=xrefwindow id=d839e1835 href="http://dx.doi.org/10.1093/cid/cix034">Publisher Full Text </a> | <a target=xrefwindow id=d839e1838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5848369">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727464249">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726253873"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1851 class=n-a></a>Falagas ME, Vouloumanou EK, Samonis G, <i> et al.</i>: Fosfomycin. <i>Clin Microbiol Rev.</i> 2016; <b>29</b>(2): 321â47. <a target=xrefwindow id=d839e1862 href="http://www.ncbi.nlm.nih.gov/pubmed/26960938">PubMed Abstract </a> | <a target=xrefwindow id=d839e1865 href="http://dx.doi.org/10.1128/CMR.00068-15">Publisher Full Text </a> | <a target=xrefwindow id=d839e1869 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4786888">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726253873">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728610112"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1882 class=n-a></a>Sastry S, Doi Y: Fosfomycin: Resurgence of an old companion. <i>J Infect Chemother.</i> 2016; <b>22</b>(5): 273â80. <a target=xrefwindow id=d839e1890 href="http://www.ncbi.nlm.nih.gov/pubmed/26923259">PubMed Abstract </a> | <a target=xrefwindow id=d839e1893 href="http://dx.doi.org/10.1016/j.jiac.2016.01.010">Publisher Full Text </a> | <a target=xrefwindow id=d839e1896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4833629">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728610112">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726289273"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e1909 class=n-a></a>Vardakas KZ, Legakis NJ, Triarides N, <i> et al.</i>: Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. <i>Int J Antimicrob Agents.</i> 2016; <b>47</b>(4): 269â85. <a target=xrefwindow id=d839e1920 href="http://www.ncbi.nlm.nih.gov/pubmed/27013000">PubMed Abstract </a> | <a target=xrefwindow id=d839e1923 href="http://dx.doi.org/10.1016/j.ijantimicag.2016.02.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726289273">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d839e1937 class=n-a></a>Roussos N, Karageorgopoulos DE, Samonis G, <i> et al.</i>: Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. <i>Int J Antimicrob Agents.</i> 2009; <b>34</b>(6): 506â15. <a target=xrefwindow id=d839e1948 href="http://www.ncbi.nlm.nih.gov/pubmed/19828298">PubMed Abstract </a> | <a target=xrefwindow id=d839e1951 href="http://dx.doi.org/10.1016/j.ijantimicag.2009.08.013">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d839e1960 class=n-a></a>Docobo-PÃ©rez F, Drusano GL, Johnson A, <i> et al.</i>: Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. <i>Antimicrob Agents Chemother.</i> 2015; <b>59</b>(9): 5602â10. <a target=xrefwindow id=d839e1971 href="http://www.ncbi.nlm.nih.gov/pubmed/26124169">PubMed Abstract </a> | <a target=xrefwindow id=d839e1974 href="http://dx.doi.org/10.1128/AAC.00752-15">Publisher Full Text </a> | <a target=xrefwindow id=d839e1978 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4538498">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d839e1987 class=n-a></a>Rosso-FernÃ¡ndez C, Sojo-Dorado J, Barriga A, <i> et al.</i>: Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum Î²-lactamase-producing <i>Escherichia coli</i> (FOREST): Study protocol for an investigator-driven randomised controlled trial. <i>BMJ Open.</i> 2015; <b>5</b>(3): e007363. <a target=xrefwindow id=d839e2001 href="http://www.ncbi.nlm.nih.gov/pubmed/25829373">PubMed Abstract </a> | <a target=xrefwindow id=d839e2005 href="http://dx.doi.org/10.1136/bmjopen-2014-007363">Publisher Full Text </a> | <a target=xrefwindow id=d839e2008 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4386243">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d839e2017 class=n-a></a>Giancola SE, Mahoney MV, Hogan MD, <i> et al.</i>: Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes. <i>Chemotherapy.</i> 2017; <b>62</b>(2): 100â4. <a target=xrefwindow id=d839e2028 href="http://www.ncbi.nlm.nih.gov/pubmed/27788499">PubMed Abstract </a> | <a target=xrefwindow id=d839e2031 href="http://dx.doi.org/10.1159/000449422">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d839e2040 class=n-a></a>Falagas ME, Kastoris AC, Karageorgopoulos DE, <i> et al.</i>: Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. <i>Int J Antimicrob Agents.</i> 2009; <b>34</b>(2): 111â20. <a target=xrefwindow id=d839e2051 href="http://www.ncbi.nlm.nih.gov/pubmed/19403273">PubMed Abstract </a> | <a target=xrefwindow id=d839e2054 href="http://dx.doi.org/10.1016/j.ijantimicag.2009.03.009">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d839e2063 class=n-a></a>Bouxom H, Fournier D, Bouiller K, <i> et al.</i>: Which non-carbapenem antibiotics are active against extended-spectrum Î²-lactamase-producing Enterobacteriaceae? <i>Int J Antimicrob Agents.</i> 2018; <b>52</b>(1): 100â3. <a target=xrefwindow id=d839e2074 href="http://www.ncbi.nlm.nih.gov/pubmed/29580930">PubMed Abstract </a> | <a target=xrefwindow id=d839e2077 href="http://dx.doi.org/10.1016/j.ijantimicag.2018.03.014">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d839e2087 class=n-a></a>Zhanel GG, Zhanel MA, Karlowsky JA: Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant <i>Escherichia coli</i>. <i>Can J Infect Dis Med Microbiol.</i> 2018; <b>2018</b>: 1404813. <a target=xrefwindow id=d839e2098 href="http://www.ncbi.nlm.nih.gov/pubmed/29666664">PubMed Abstract </a> | <a target=xrefwindow id=d839e2101 href="http://dx.doi.org/10.1155/2018/1404813">Publisher Full Text </a> | <a target=xrefwindow id=d839e2105 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5831921">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727104298"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e2114 class=n-a></a>Grabein B, Graninger W, RodrÃ­guez BaÃ±o J, <i> et al.</i>: Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. <i>Clin Microbiol Infect.</i> 2017; <b>23</b>(6): 363â72. <a target=xrefwindow id=d839e2125 href="http://www.ncbi.nlm.nih.gov/pubmed/27956267">PubMed Abstract </a> | <a target=xrefwindow id=d839e2128 href="http://dx.doi.org/10.1016/j.cmi.2016.12.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727104298">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d839e2141 class=n-a></a>Cha MK, Kang CI, Kim SH, <i> et al.</i>: <i>In vitro</i> activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-Î²-lactamase-producing <i>Escherichia coli</i> isolates causing bacteremia. <i>Antimicrob Agents Chemother.</i> 2015; <b>59</b>(9): 5834â7. <a target=xrefwindow id=d839e2159 href="http://www.ncbi.nlm.nih.gov/pubmed/26124174">PubMed Abstract </a> | <a target=xrefwindow id=d839e2162 href="http://dx.doi.org/10.1128/AAC.01121-15">Publisher Full Text </a> | <a target=xrefwindow id=d839e2165 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4538563">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d839e2174 class=n-a></a>Ipekci T, Seyman D, Berk H, <i> et al.</i>: Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i>. <i>J Infect Chemother.</i> 2014; <b>20</b>(12): 762â7. <a target=xrefwindow id=d839e2192 href="http://www.ncbi.nlm.nih.gov/pubmed/25179392">PubMed Abstract </a> | <a target=xrefwindow id=d839e2195 href="http://dx.doi.org/10.1016/j.jiac.2014.08.007">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729181767"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e2204 class=n-a></a>Cho SY, Choi SM, Park SH, <i> et al.</i>: Amikacin therapy for urinary tract infections caused by extended-spectrum Î²-lactamase-producing <i>Escherichia coli</i>. <i>Korean J Intern Med.</i> 2016; <b>31</b>(1): 156â61. <a target=xrefwindow id=d839e2218 href="http://www.ncbi.nlm.nih.gov/pubmed/26767869">PubMed Abstract </a> | <a target=xrefwindow id=d839e2222 href="http://dx.doi.org/10.3904/kjim.2016.31.1.156">Publisher Full Text </a> | <a target=xrefwindow id=d839e2225 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4712420">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729181767">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d839e2238 class=n-a></a>Zhanel GG, Lawson CD, Zelenitsky S, <i> et al.</i>: Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. <i>Expert Rev Anti Infect Ther.</i> 2012; <b>10</b>(4): 459â73. <a target=xrefwindow id=d839e2249 href="http://www.ncbi.nlm.nih.gov/pubmed/22512755">PubMed Abstract </a> | <a target=xrefwindow id=d839e2252 href="http://dx.doi.org/10.1586/eri.12.25">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d839e2262 class=n-a></a>Karaiskos I, Souli M, Giamarellou H: Plazomicin: an investigational therapy for the treatment of urinary tract infections. <i>Expert Opin Investig Drugs.</i> 2015; <b>24</b>(11): 1501â11. <a target=xrefwindow id=d839e2270 href="http://www.ncbi.nlm.nih.gov/pubmed/26419762">PubMed Abstract </a> | <a target=xrefwindow id=d839e2273 href="http://dx.doi.org/10.1517/13543784.2015.1095180">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718180350"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e2282 class=n-a></a>Livermore DM, Mushtaq S, Warner M, <i> et al.</i>: Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. <i>J Antimicrob Chemother.</i> 2011; <b>66</b>(1): 48â53. <a target=xrefwindow id=d839e2293 href="http://www.ncbi.nlm.nih.gov/pubmed/21078604">PubMed Abstract </a> | <a target=xrefwindow id=d839e2296 href="http://dx.doi.org/10.1093/jac/dkq408">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718180350">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d839e2309 class=n-a></a>Walkty A, Adam H, Baxter M, <i> et al.</i>: <i>In vitro</i> activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(5): 2554â63. <a target=xrefwindow id=d839e2323 href="http://www.ncbi.nlm.nih.gov/pubmed/24550325">PubMed Abstract </a> | <a target=xrefwindow id=d839e2327 href="http://dx.doi.org/10.1128/AAC.02744-13">Publisher Full Text </a> | <a target=xrefwindow id=d839e2330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3993217">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d839e2339 class=n-a></a>Balakrishnan I, Awad-El-Kariem FM, Aali A, <i> et al.</i>: Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC Î²-lactamase-producing Enterobacteriaceae. <i>J Antimicrob Chemother.</i> 2011; <b>66</b>(11): 2628â31. <a target=xrefwindow id=d839e2350 href="http://www.ncbi.nlm.nih.gov/pubmed/21810837">PubMed Abstract </a> | <a target=xrefwindow id=d839e2353 href="http://dx.doi.org/10.1093/jac/dkr317">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d839e2362 class=n-a></a>Laterre PF, Wittebole X, Van de Velde S, <i> et al.</i>: Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. <i>J Antimicrob Chemother.</i> 2015; <b>70</b>(3): 891â8. <a target=xrefwindow id=d839e2373 href="http://www.ncbi.nlm.nih.gov/pubmed/25433006">PubMed Abstract </a> | <a target=xrefwindow id=d839e2376 href="http://dx.doi.org/10.1093/jac/dku465">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726209861"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e2385 class=n-a></a>Mazuski JE, Gasink LB, Armstrong J, <i> et al.</i>: Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. <i>Clin Infect Dis.</i> 2016; <b>62</b>(11): 1380â9. <a target=xrefwindow id=d839e2396 href="http://www.ncbi.nlm.nih.gov/pubmed/26962078">PubMed Abstract </a> | <a target=xrefwindow id=d839e2399 href="http://dx.doi.org/10.1093/cid/ciw133">Publisher Full Text </a> | <a target=xrefwindow id=d839e2403 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872289">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726209861">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d839e2417 class=n-a></a>Carmeli Y, Armstrong J, Newell P, <i> et al.</i>: Ceftazidime-avibactam in ceftazidime-resistant infections. <i>Lancet Infect Dis.</i> 2016; <b>16</b>(9): 997â8. <a target=xrefwindow id=d839e2428 href="http://www.ncbi.nlm.nih.gov/pubmed/27684334">PubMed Abstract </a> | <a target=xrefwindow id=d839e2431 href="http://dx.doi.org/10.1016/S1473-3099(16)30265-1">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d839e2440 class=n-a></a>[Internet]. AAscc-avmihawnpICg, <a target=xrefwindow id=d839e2442 href="https://clinicaltrials.gov/ct2/show/NCT01808092">Reference Source</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d839e2451 class=n-a></a>Sucher AJ, Chahine EB, Cogan P, <i> et al.</i>: Ceftolozane/Tazobactam: A New Cephalosporin and Î²-Lactamase Inhibitor Combination. <i>Ann Pharmacother.</i> 2015; <b>49</b>(9): 1046â56. <a target=xrefwindow id=d839e2462 href="http://www.ncbi.nlm.nih.gov/pubmed/26160970">PubMed Abstract </a> | <a target=xrefwindow id=d839e2465 href="http://dx.doi.org/10.1177/1060028015593293">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726065679"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d839e2474 class=n-a></a>Scott LJ: Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. <i>Drugs.</i> 2016; <b>76</b>(2): 231â42. <a target=xrefwindow id=d839e2482 href="http://www.ncbi.nlm.nih.gov/pubmed/26746849">PubMed Abstract </a> | <a target=xrefwindow id=d839e2485 href="http://dx.doi.org/10.1007/s40265-015-0524-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726065679">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d839e2498 class=n-a></a>Merck Sharp &amp; Dohme Corp: ZerbaxaTM (ceftolozane and tazobactam) for injection fiuUpihzc. </span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d839e2507 class=n-a></a>Solomkin J, Hershberger E, Miller B, <i> et al.</i>: Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). <i>Clin Infect Dis.</i> 2015; <b>60</b>(10): 1462â71. <a target=xrefwindow id=d839e2518 href="http://www.ncbi.nlm.nih.gov/pubmed/25670823">PubMed Abstract </a> | <a target=xrefwindow id=d839e2521 href="http://dx.doi.org/10.1093/cid/civ097">Publisher Full Text </a> | <a target=xrefwindow id=d839e2525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4412191">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d839e2535 class=n-a></a>Lucasti C, Hershberger E, Miller B, <i> et al.</i>: Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(9): 5350â7. <a target=xrefwindow id=d839e2546 href="http://www.ncbi.nlm.nih.gov/pubmed/24982069">PubMed Abstract </a> | <a target=xrefwindow id=d839e2549 href="http://dx.doi.org/10.1128/AAC.00049-14">Publisher Full Text </a> | <a target=xrefwindow id=d839e2553 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4135839">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d839e2562 class=n-a></a>Wagenlehner FM, Umeh O, Darouiche RO: Ceftolozane-tazobactam versus levofloxacin in urinary tract infection - Authors' reply. <i>Lancet.</i> 2015; <b>386</b>(10000): 1242. <a target=xrefwindow id=d839e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/26460659">PubMed Abstract </a> | <a target=xrefwindow id=d839e2573 href="http://dx.doi.org/10.1016/S0140-6736(15)00263-9">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1347.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1347.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Infectious Diseases Department, 3rd Department of Pediatrics, Hippokration General Hospital Aristotle University, Thessaloniki, Greece<br/> <sup>2</sup> Infectious Diseases Department, The Children&rsquo;s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA<br/> <p> <div class=margin-bottom> Zoi Dorothea Pana <br/> <span>Roles: </span> Writing â Original Draft Preparation </div> <div class=margin-bottom> Theoklis Zaoutis <br/> <span>Roles: </span> Writing â Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1347/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 29 Aug 2018, 7:1347 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14822.1">https://doi.org/10.12688/f1000research.14822.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> Â© 2018 Pana ZD and Zaoutis T. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16132 data-id=14822 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14822.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1347/v1/pdf?article_uuid=60d938ba-2430-4045-bf09-c48fdce4da42" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14822.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Pana ZD and Zaoutis T. Treatment of extended-spectrum Î²-lactamase-producing <i>Enterobacteriaceae </i>(ESBLs) infections: what have we learned until now? [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1347 (<a href="https://doi.org/10.12688/f1000research.14822.1" target=_blank>https://doi.org/10.12688/f1000research.14822.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14822 id=mobile-track-article-signin-14822 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14822?target=/articles/7-1347.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16132 /> <input name=articleId type=hidden value=14822 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jean-Ralph Zahar</strong>, Infection Control Unit, HÃ´pital Avicenne (AP-HP), France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Patrice Nordmann</strong>, Medical and Molecular Microbiology, Faculty of Science and Medicine, National Reference Center for Emerging Antibiotic Resisance and Foreign Reserach Unit (INSERM, France) University of Fribourg, Switzerland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1347.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1347.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=38332-37545></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=26696-37546></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1347/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>29 Aug 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jean-Ralph Zahar</strong>, Infection Control Unit, HÃ´pital Avicenne (AP-HP), France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Patrice Nordmann</strong>, Medical and Molecular Microbiology, Faculty of Science and Medicine, National Reference Center for Emerging Antibiotic Resisance and Foreign Reserach Unit (INSERM, France) University of Fribourg, Switzerland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1347.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1347/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Treatment of extended-spectrum \u03B2-lactamase-producing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1347/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1347/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1347/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Pana ZD and Zaoutis T');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1347/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1347",
            templates : {
                twitter : "Treatment of extended-spectrum \u03B2-lactamase-producing Enterobacteriaceae.... Pana ZD and Zaoutis T, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1347/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Treatment of extended-spectrum \u03B2-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Treatment of extended-spectrum \u03B2-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14822/16132")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16132");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "37545": 0,
                           "37546": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "45bb0135-5d11-41fb-b1a8-fef758151eec";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1347.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1347.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1347.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1347.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1347.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>